膜杰作
Star Staining
优势与特点（FAB）
- Cost effective - Sufficient quantity at a lower price, accounting for dilution and pipetting losses.
- Comprehensive validation - Validated with various antibody subtypes and antibody drugs.
- Simple and fast operation - No complicated washing steps, significantly reducing time.
- High batch consistency - Strict control over raw materials and finished product quality, ensuring a stable supply.
- Accurate and reliable results - High sensitivity with minimal matrix effects.
- High throughput capability - Supports 500 tests, ideal for high-throughput screening.
- Fast completion - Results in just 1 hour.
产品参数（Product Specifications）
| Assay Type | Inhibition-TR-FRET |
| Analyte | Human IgG, Human IgG Fc protein, Human FcRn inhibitors, Anti-human FcRn antibody |
| Format | 100T/500T |
| Reactivity | Human |
| Regulatory Status | RUO |
| Sensitivity | IC50=20.14μg/mL |
| Standard Curve Range | 0.24 μg/mL-1000 μg/mL |
| Assay Time | 1 hr |
| Suitable Sample Type | For the binding of IgG Fc region to the human FcRn receptor |
| Sample volume | 10 μL |
产品概述（Product Overview）
The Human FcRn binding Kit (TR-FRET) is based on a homogeneous (no wash) competition TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer) to measure the interaction between human FcRn and antibody drug candidates or FcRn inhibitors. It is designed to facilitate the half-life evaluation of antibody drug candidates, high-throughput screening of FcRn inhibitors within 0.5-1 hours. It can also be used as a universal detection tool to identify the ability of antibody drugs to bind to FcRn.
存储（Storage）
组分（Materials Provided）
| ID | Components | Size |
| FRT01-C01 | Human FCRN&B2M Heterodimer Protein Europium-chelate | 100 tests/500 tests |
| FRT01-C02 | FA labeled human IgG antibody | 100 tests/500 tests |
| FRT01-C03 | Human IgG standard | 200 μg/100 tests
1 mg/500 tests |
| FRT01-C04 | Sample Dilution Buffer | 10 mL/100tests & 500tests |
| FRT01-C05 | Detection Buffer | 10 mL/100tests & 500tests |
原理（Assay Principles）
This Human FcRn binding Kit (TR-FRET) is based on TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer). Use the mixture of biotinylated FcRn and Europium-chelate labeled streptavidin as the donor, FA labeled Human IgG1 antibody as the acceptor.
- In the absence of FcRn-binding components, the donor and acceptor are in close proximity due to the binding of FcRn and FA-labeled Human IgG1 antibody. The donor emits a 620 nm signal upon excitation, which is absorbed by the acceptor, resulting in a 665 nm emission.
- In the presence of FcRn-binding components, they interfere with the donor-acceptor interaction, preventing FRET from occurring.
活性（Bioactivity）-TR-FRET Please refer to DS document for the assay protocol.
Inhibition Assay of interaction of Human FcRn and Human IgG1 antibody by Human IgG standard in a homogeneous (no wash) TR-FRET (Time-Resolved Fluorescence Resonance Energy Transfer) competition assay, with a typical IC50 of 20.14 μg/mL (QC tested).
The kit has been used to detect different subclasses of Human IgG Fc proteins, which exhibit different IC50 results as expected.
The kit has been used to detect different subclasses of Human IgG, which exhibit different IC50 results as expected.
The kit has been used to detect the binding activity between Human FcRn and Human IgG standard under different pH. The IC50 shows a significant increase with increasing pH, which corelates with a decreased binding between Human FcRn and Human IgG standard.
The half-lives of these 3 monoclonal antibodies currently in clinical use generally correlate with the binding affinity to FcRn. The kit has been used to detect 3 FDA approved antibody drugs of different binding affinity to FcRn, and the IC50 trends are consistent with affinity constant from SPR as well as the actual in vivo half-life published.
The kit is suitable for the detection of FcRn inhibitors. It shows that both Efgartigimod and its biosimilar, Human IgG1 Fc (C103S, M135Y, S137T, T139E, H316K, N317F) His Tag (Cat. No. IG1-H52H8) exhibit good inhibitory activity in this TR-FRET competition assay.
